What's Happening?
Delcath Systems, Inc., an interventional oncology company, has commenced a Phase 2 clinical trial for its HEPZATO KIT in combination with standard care treatments for liver-dominant metastatic colorectal cancer (mCRC). The trial, which has dosed its first patient at the City of Hope National Medical Center, aims to evaluate the safety and efficacy of HEPZATO combined with trifluridine-tipiracil and bevacizumab. The study will enroll approximately 90 patients across more than 20 sites in the U.S. and Europe. The primary endpoint is hepatic progression-free survival, with results expected by mid-2028. Delcath's HEPZATO KIT is designed to deliver high-dose chemotherapy directly to the liver, minimizing systemic exposure and side effects.
AD
Why It's Important?
This trial represents a significant step in addressing the unmet medical needs of patients with liver-dominant mCRC, a condition with limited treatment options. The success of this trial could lead to a new therapeutic option for a patient population that currently faces significant challenges in treatment. The potential market for this treatment in the U.S. is estimated to be between 6,000 and 10,000 patients annually. Positive outcomes from this trial could enhance Delcath's market position and provide a new revenue stream, while also contributing to advancements in cancer treatment methodologies.
What's Next?
The trial will continue to enroll patients and gather data on the efficacy and safety of the HEPZATO KIT in combination with standard treatments. Delcath will monitor the trial's progress and prepare for potential regulatory submissions based on the trial outcomes. The company will also engage with the medical community to discuss the implications of the trial results and explore further applications of its technology in other cancer types.
